Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 9/20 | 0.42 |
| ▸ | AXL | P30530 | 5/20 | 0.41 |
| ▸ | SRC | P12931 | 3/20 | 0.39 |
| ▸ | WEE1 | P30291 | 2/20 | 0.39 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035439 | 0.86 | TNK2 (0.44) | TNK2AXLSRCWEE1CAMK2D | |
| SCHEMBL15035316 | 0.82 | TNK2 (0.45) | TNK2AXLSRCWEE1CAMK2D | |
| SCHEMBL15035366 | 0.81 | CDK4 (0.39) | AXLSRCWEE1CDK4CCNA2 | |
| SCHEMBL15035395 | 0.78 | CDK4 (0.37) | TNK2SRCWEE1CDK4CCNA2 | |
| SCHEMBL15035499 | 0.78 | TNK2 (0.44) | TNK2AXLSRCWEE1EGFR | |
| SCHEMBL15041555 | 0.76 | CDK4 (0.41) | CAMK2DCDK4CCNA2CCND1CDK2 | |
| SCHEMBL15041292 | 0.76 | MAPK8 (0.41) | WEE1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL15035330 | 0.76 | CDK4 (0.37) | AXLRIPK2ACVR1NOD2CDK4 | |
| SCHEMBL15035396 | 0.76 | TNK2 (0.48) | TNK2AXLSRCEGFR | |
| SCHEMBL15034808 | 0.74 | TNK2 (0.48) | TNK2AXLSRCWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885AXL 1075/4885SRC 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.